Home » GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES
GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES
GlaxoSmithKline Plc has signed a deal to licence in a substantial portfolio of tumour-specific antigens from the international
Ludwig Institute for Cancer Research to boost its cancer vaccine portfolio.
The Scotsman
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May